{"title":"Statins do not affect bone anabolism in older women treated with teriparatide.","authors":"Cecilia Oliveri, Anastasia Xourafa, Nunziata Morabito, Agostino Gaudio, Ilaria Politi, Peter Schwartz, Salvatore Minisola, Antonino Catalano","doi":"10.1210/clinem/dgaf523","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Teriparatide [rhPTH (1-34)] is an established anabolic agent for the treatment of severe osteoporosis. Statins, HMG-CoA reductase inhibitors, have demonstrated antiresorptive properties, but their impact on the anabolic efficacy of rhPTH remains unclear.</p><p><strong>Objective: </strong>To evaluate whether concurrent statin therapy influences changes in bone mineral density (BMD) and bone turnover markers in women receiving rhPTH.</p><p><strong>Methods: </strong>This retrospective cohort study included 104 postmenopausal women with severe osteoporosis who completed 24 months of daily rhPTH (20 mcg subcutaneously) and biweekly cholecalciferol (25,000 IU). Patients were stratified by statin use. BMD at the lumbar spine and femoral neck was assessed at baseline and study completion. Bone turnover markers-alkaline phosphatase (ALP), osteocalcin (OCN), and C-terminal telopeptide of type I collagen (CTX)-were measured every six months.</p><p><strong>Results: </strong>Thirty patients were statin users and seventy-four were non-users. Statin users experienced lumbar spine BMD gain from 0.71±0.16 to 0.79±0.14 g/cm² (p=0.01), and a trend toward femoral neck improvement from 0.53±0.24 to 0.62±0.12 g/cm² (p=0.07). Non-users also showed lumbar spine BMD rise from 0.70±0.10 to 0.77±0.11 g/cm² (p=0.001), with no significant femoral neck BMD change from 0.60±0.11 to 0.58±0.15 g/cm² (p=0.5). At the end of the observation period, CTX levels were significantly lower in statin users compared to non-users (0.37±0.29 vs 0.66±0.47 ng/mL, p=0.007). Conversely, no significant intergroup differences were observed for ALP and OCN throughout the observation period.</p><p><strong>Conclusion: </strong>Statin use does not impair the anabolic efficacy of rhPTH in increasing BMD in postmenopausal women with severe osteoporosis, and it provides additional antiresorptive benefits during rhPTH therapy. These findings support the continued use of statins and highlight the need for further prospective studies exploring synergistic effects.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of clinical endocrinology and metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/clinem/dgaf523","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Context: Teriparatide [rhPTH (1-34)] is an established anabolic agent for the treatment of severe osteoporosis. Statins, HMG-CoA reductase inhibitors, have demonstrated antiresorptive properties, but their impact on the anabolic efficacy of rhPTH remains unclear.
Objective: To evaluate whether concurrent statin therapy influences changes in bone mineral density (BMD) and bone turnover markers in women receiving rhPTH.
Methods: This retrospective cohort study included 104 postmenopausal women with severe osteoporosis who completed 24 months of daily rhPTH (20 mcg subcutaneously) and biweekly cholecalciferol (25,000 IU). Patients were stratified by statin use. BMD at the lumbar spine and femoral neck was assessed at baseline and study completion. Bone turnover markers-alkaline phosphatase (ALP), osteocalcin (OCN), and C-terminal telopeptide of type I collagen (CTX)-were measured every six months.
Results: Thirty patients were statin users and seventy-four were non-users. Statin users experienced lumbar spine BMD gain from 0.71±0.16 to 0.79±0.14 g/cm² (p=0.01), and a trend toward femoral neck improvement from 0.53±0.24 to 0.62±0.12 g/cm² (p=0.07). Non-users also showed lumbar spine BMD rise from 0.70±0.10 to 0.77±0.11 g/cm² (p=0.001), with no significant femoral neck BMD change from 0.60±0.11 to 0.58±0.15 g/cm² (p=0.5). At the end of the observation period, CTX levels were significantly lower in statin users compared to non-users (0.37±0.29 vs 0.66±0.47 ng/mL, p=0.007). Conversely, no significant intergroup differences were observed for ALP and OCN throughout the observation period.
Conclusion: Statin use does not impair the anabolic efficacy of rhPTH in increasing BMD in postmenopausal women with severe osteoporosis, and it provides additional antiresorptive benefits during rhPTH therapy. These findings support the continued use of statins and highlight the need for further prospective studies exploring synergistic effects.